Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Compare

1,565 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NKTR Analyst Ratings

Moderate Buy

7 Buy

1 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Nektar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

$103.88

▲(121.78% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $103.88 with a high forecast of $135.00 and a low forecast of $30.00. The average price target represents a 121.78% change from the last price of $46.84.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","40":"$40","72":"$72","104":"$104","136":"$136"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$103.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,40,72,104,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,66.79384615384615,72.47769230769231,78.16153846153846,83.84538461538462,89.52923076923076,95.21307692307693,100.89692307692307,106.58076923076922,112.26461538461538,117.94846153846154,123.63230769230769,129.31615384615384,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,64.4,67.69,70.98,74.27,77.56,80.85,84.14,87.42999999999999,90.72,94.00999999999999,97.3,100.59,{"y":103.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.11,58.716923076923074,56.323846153846155,53.93076923076923,51.53769230769231,49.144615384615385,46.75153846153846,44.35846153846154,41.965384615384615,39.57230769230769,37.17923076923077,34.786153846153844,32.39307692307692,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$135.00

Average Price Target$103.88

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Roger Song

Jefferies

$121

Buy

158.33%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)

Julian Harrison

BTIG

$100→$118

Buy

151.92%

Upside

Reiterated

12/16/25

Promising Data from REZOLVE-AA Trial Positions REZPEG as a Safer, Effective Treatment for Alopecia Areata with Undervalued Stock

Arthur He CFA

H.C. Wainwright

$120→$135

Buy

188.22%

Upside

Reiterated

12/16/25

Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target

Jay Olson

Oppenheimer

$98→$115

Buy

145.52%

Upside

Reiterated

12/16/25

Nektar price target raised to $115 from $98 at OppenheimerNektar price target raised to $115 from $98 at Oppenheimer

Andy Hsieh

William Blair

Hold

―

Reiterated

12/16/25

Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results

Samantha Semenkow

Citi

$102

Buy

117.76%

Upside

Reiterated

12/16/25

Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment

Yasmeen Rahimi

Piper Sandler

$105

Buy

124.17%

Upside

Reiterated

11/25/25

Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler

Jessica Fye

J.P. Morgan

$30

Sell

-35.95%

Downside

Reiterated

11/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)

Mayank Mamtani

B. Riley Securities

$85→$105

Buy

124.17%

Upside

Reiterated

09/23/25

B. Riley Securities Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Roger Song

Jefferies

$121

Buy

158.33%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)

Julian Harrison

BTIG

$100→$118

Buy

151.92%

Upside

Reiterated

12/16/25

Promising Data from REZOLVE-AA Trial Positions REZPEG as a Safer, Effective Treatment for Alopecia Areata with Undervalued Stock

Arthur He CFA

H.C. Wainwright

$120→$135

Buy

188.22%

Upside

Reiterated

12/16/25

Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target

Jay Olson

Oppenheimer

$98→$115

Buy

145.52%

Upside

Reiterated

12/16/25

Nektar price target raised to $115 from $98 at OppenheimerNektar price target raised to $115 from $98 at Oppenheimer

Andy Hsieh

William Blair

Hold

―

Reiterated

12/16/25

Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results

Samantha Semenkow

Citi

$102

Buy

117.76%

Upside

Reiterated

12/16/25

Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment

Yasmeen Rahimi

Piper Sandler

$105

Buy

124.17%

Upside

Reiterated

11/25/25

Nektar Therapeutics (NKTR) Gets a Buy from Piper Sandler

Jessica Fye

J.P. Morgan

$30

Sell

-35.95%

Downside

Reiterated

11/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)

Mayank Mamtani

B. Riley Securities

$85→$105

Buy

124.17%

Upside

Reiterated

09/23/25

B. Riley Securities Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

1 Month

xxx

Success Rate

10/21 ratings generated profit

Average Return

+0.95%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of +0.95% per trade.

3 Months

xxx

Success Rate

12/21 ratings generated profit

Average Return

+1.87%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +1.87% per trade.

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

8/10 ratings generated profit

Average Return

+138.66%

reiterated a buy rating 26 days ago

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +138.66% per trade.

2 Years

xxx

Success Rate

8/10 ratings generated profit

Average Return

+132.63%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +132.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NKTR has received 15 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. NKTR average Analyst price target in the past 3 months is 103.88.

Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -$2.42 with a range of -$3.68 to -$1.66. The previous quarter’s EPS was -$1.87. NKTR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is $10.04M with a range of $6.90M to $15.81M. The previous quarter’s sales results were $11.79M. NKTR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Stock Forecast FAQ

What is NKTR’s average 12-month price target, according to analysts?

Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 103.88.

What is NKTR’s upside potential, based on the analysts’ average price target?

Nektar Therapeutics has 121.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NKTR a Buy, Sell or Hold?

Nektar Therapeutics has a consensus rating of Moderate Buy which is based on 7 buy ratings, 1 hold ratings and 1 sell ratings.

What is Nektar Therapeutics’s price target?

The average price target for Nektar Therapeutics is 103.88. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $30.00. The average price target represents 121.78% Increase from the current price of $46.84.

What do analysts say about Nektar Therapeutics?

Nektar Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of NKTR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

NKTR Analyst Ratings

NKTR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nektar Therapeutics

NKTR Analyst Recommendation Trends

NKTR Financial Forecast

NKTR Earnings Forecast

NKTR Sales Forecast

NKTR Stock Forecast FAQ

Detailed List of Analyst Forecasts